Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.

Scientific reports - 21 Jan 2023

Bhiman Jinal N, Richardson Simone I, Lambson Bronwen E, Kgagudi Prudence, Mzindle Nonkululeko, Kaldine Haajira, Crowther Carol, Gray Glenda, Bekker Linda-Gail, Shinde Vivek, Bennett Chijioke, Glenn Gregory M, Madhi Shabir A, Moore Penny L

Abstract excerpt

The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating variants. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine containing the ancestral spike sequence, has value in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to Mutation

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 36681693
DOI: 10.1038/s41598-023-27698-x
PMCID: PMC9867547

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.PMID 36681693Read ↗

Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical TrialSemantic proximity Read ↗

mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron VariantSemantic proximity Read ↗

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trialSemantic proximity Read ↗

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine boosterSemantic proximity Read ↗

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwaySemantic proximity Read ↗

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.Semantic proximity Read ↗

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinationsSemantic proximity Read ↗

Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccinesSemantic proximity Read ↗

Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccinesSemantic proximity Read ↗

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanismSemantic proximity Read ↗

Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineagesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.